Publication: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission
Issued Date
2000-01-26
Resource Type
ISSN
00221899
DOI
Other identifier(s)
2-s2.0-0242289041
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infectious Diseases. Vol.181, No.1 (2000), 99-106
Suggested Citation
Rutt Chuachoowong, Nathan Shaffer, Wimol Siriwasin, Pongsakdi Chaisilwattana, Nancy L. Young, Philip A. Mock, Sanay Chearskul, Naris Waranawat, Thongpoon Chaowanachan, John Karon, R. J. Simonds, Timothy D. Mastro Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Journal of Infectious Diseases. Vol.181, No.1 (2000), 99-106. doi:10.1086/315179 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26292
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission
Abstract
Human immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P < .001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P < .001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1 times (95% confidence interval, 0.9-3.5 vs. 2.4-15.4) for women with and without quantifiable CVL HIV-1, respectively (P = .03). CVL HIV-1 is an independent risk factor for perinatal HIV-1 transmission.